Patents by Inventor Enrico G. Baggiolini

Enrico G. Baggiolini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5512554
    Abstract: Compounds of the formula ##STR1## wherein R is hydrogen, hydroxy, or fluorine, and X is H.sub.2 or .dbd.CH.sub.2 are useful as agents for the treatment of hyperproliferative disorders of the skin such as psoriasis, as agents for the treatment of cancer, such as, leukemia, and as agents for the treatment of sebaceous gland diseases, such as, acne and seborrheic dermatitis.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: April 30, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, deceased, Shian-Jan Shiuey, Milan R. Uskokovic
  • Patent number: 5451574
    Abstract: Compounds of the formula ##STR1## wherein R is hydrogen, hydroxy, or fluorine, and X is H.sub.2 are useful as agents for the treatment of hyperproliferative disorders of the skin such as psoriasis, as agents for the treatment of cancer, such as, leukemia, and as agents for the treatment of sebaceous gland diseases, such as, acne and seborrheic dermatitis.
    Type: Grant
    Filed: January 18, 1994
    Date of Patent: September 19, 1995
    Assignee: Hoffman-La Roche Inc.
    Inventors: Enrico G. Baggiolini, deceased, Barbara J. Baggiolini, Shian-Jan Shiuey, Milan R. Uskokovic
  • Patent number: 5247123
    Abstract: The invention is directed to deuterated vitamin D analogs, and processes and intermediates for their preparation. The end products, that is the deuterated vitamin D analogs, are useful for the treatment osteoporosis and cutaneous inflammations such as psoriasis, and contact dermatitis.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: September 21, 1993
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Bernard M. Hennessy, Milan R. Uskokovic
  • Patent number: 5149846
    Abstract: The invention is directed to deuterated vitamin D analogs, and processes and intermediates for their preparation. The end products, that is the deuterated vitamin D analogs, are useful for the treatment osteoporosis and cutaneous inflammations such as psoriasis, and contact dermatitis.
    Type: Grant
    Filed: November 16, 1989
    Date of Patent: September 22, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Bernard M. Hennessy, Milan R. Uskokovic
  • Patent number: 5145846
    Abstract: Compounds of the formula ##STR1## wherein R is hydrogen or hydroxy, R.sub.5 is hydrogen, and A is ##STR2## with the proviso that when A is --C.tbd.C--, R.sub.5 may also be deuterium, are described.The compounds of formula I are useful as agents for the treatment of hyperproliferative disorders of the skin such as psoriasis, as agents for the treatment of neoplastic diseases such as leukemia, and as agents for the treatment of sebaceous gland diseases such as acne or seborrheic dermatitis.
    Type: Grant
    Filed: April 10, 1991
    Date of Patent: September 8, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, deceased, Bernard M. Hennessy, Shian-Jan Shiuey, Gary A. Truitt, Milan R. Uskokovic
  • Patent number: 5120722
    Abstract: The compounds 1.alpha.,25(S), 26-trihydroxy-.DELTA..sup.22 -cholecalciferol; 1.alpha.,25(R), 26-trihydroxy-.DELTA..sup.22 -cholecalciferol; 1.alpha.,25(S),26-trihydroxyergocalciferol, 1.alpha.,25(R),26-trihydroxyergocalciferol and pharmaceutical compositions comprising the compounds as well as methods of making and using these compounds are disclosed.
    Type: Grant
    Filed: March 19, 1990
    Date of Patent: June 9, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Andrew D. Batcho, Gary A. Truitt, Milan R. Uskokovic, Peter M. Wovkulich
  • Patent number: 5110958
    Abstract: The claimed invention relates to intermediate compounds of the formula ##STR1## wherein R is hydrogen or methyl, R.sub.1 and R.sub.2 each, independently, is hydrogen, lower alkyl or aryl, or taken together are lower alkylene of from 3 to 6 carbon atoms, and the dotted (. . . ) line is an optional bond.
    Type: Grant
    Filed: May 6, 1991
    Date of Patent: May 5, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Andrew D. Batcho, Gary A. Truitt, Milan R. Uskokovic, Peter M. Wovkulich
  • Patent number: 5087619
    Abstract: Compounds of the formula ##STR1## wherein R is hydrogen or hydroxy, R.sub.5 is hydrogen, and A is --C.tbd.C--, ##STR2## or --CH.sub.2 --CH.sub.2 --, with the proviso that when A is --C.tbd.C--, R.sub.5 may also be deuterium, are described.The compounds of formula I are useful as agents for the treatment of hyperproliferative disorders of the skin such as psoriasis, as agents for the treatment of neoplastic diseases such as leukemia, and as agents for the treatment of sebaceous gland diseases such as acne or seborrheic dermatitis.
    Type: Grant
    Filed: March 23, 1990
    Date of Patent: February 11, 1992
    Assignee: Hoffman-La Roche Inc.
    Inventors: Enrico G. Baggiolini, deceased, Barbara J. Baggiolini, Bernard M. Hennessy, Shian-Jan Shiuey, Gary A. Truitt, Milan R. Uskokovic
  • Patent number: 5039671
    Abstract: 26, 26, 26-Trifluoro-1.alpha., 25-dihydroxy-cholecalciferol, and the 25R or 25S epimer thereof, are described, as well as processes and intermediates utilized to prepare the same, as well as pharmaceutical compositions containing the same. 26,26,26-trifluoro 1.alpha., 25-dihydroxycholecalciferol and the 25R or 25S epimer thereof are useful agents in the treatment of disease states such as osteoporosis, oseodystrophy and leukemia.
    Type: Grant
    Filed: November 16, 1989
    Date of Patent: August 13, 1991
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Giacomo Pizzolato, Gary A. Truitt, Milan R. Uskokovic
  • Patent number: 4906785
    Abstract: 26,26,26-Trifluoro-1.alpha.,25-dihydroxy-cholecalciferol, and the 25R or 25S epimer thereof, are described, as well as processes and intermediates utilized to prepare the same, as well as pharmaceutical compositions containing the same. 26,26,26-trifluoro 1.alpha.,25-dihydroxycholecalciferol and the 25R or 25S epimer thereof are useful agents in the treatment of disease states such as osteoporosis, osteodystrophy and leukemia.
    Type: Grant
    Filed: January 22, 1986
    Date of Patent: March 6, 1990
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Giacomo Pizzolato, Gary A. Truitt, Milan R. Uskovic
  • Patent number: 4898855
    Abstract: The invention is directed to deuterated vitamin D analogs, and processes and intermediates for their preparation. The end products, that is the deuterated vitamin D analogs, are useful for the treatment osteoporosis and cutaneous inflammations such as psoriasis, and contact dermatitis.
    Type: Grant
    Filed: September 14, 1987
    Date of Patent: February 6, 1990
    Assignee: Hoffman-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Bernard M. Hennessy, Milan R. Uskokovic
  • Patent number: 4804502
    Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydrogen or fluorine are described. The compounds of formula I are useful as agents in the treatment of disease states characterized by metabolic calcium deficiencies. Examplary of such disease states are osteoporosis and renal osteodystrophy.
    Type: Grant
    Filed: January 20, 1988
    Date of Patent: February 14, 1989
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, John J. Partridge, Shian-Jan Shiuey, Gary A. Truitt, Milan R. Uskokovic
  • Patent number: 4632784
    Abstract: The invention is directed to a process and intermediates for the preparation of 1.alpha., 23,25-trihydroxycholecalciferol-26-oic acid 23,26-lactone.
    Type: Grant
    Filed: July 30, 1984
    Date of Patent: December 30, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Milan R. Uskokovic, Peter M. Wovkulich
  • Patent number: 4612308
    Abstract: The syntheses of 25,26-dehydro-1.alpha.,23S-dihydroxycholecalciferol, 25,26-dehydro-1.alpha.,23R-dihydroxycholecalciferol, and the epimeric mixture thereof which are useful as differentiation inducing agents and anti-proliferation agents are described, 25,26-dehydro-1.alpha.,23S-dihydroxycholecalciferol 25,26-dehydro-1.alpha.,23R-dihydroxycholecalciferol and the epimeric mixture thereof are useful for treating tumors and leukemia, and osteoporosis.
    Type: Grant
    Filed: November 29, 1984
    Date of Patent: September 16, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Gary A. Truitt, Milan R. Uskokovic, Peter M. Wovkulich
  • Patent number: 4595776
    Abstract: The invention is directed to a process and intermediates for the preparation of 1.alpha.,25-dihydroxyergocalciferol as well as substantially pure and crystalline 1.alpha.,25-dihydroxyergocolciferol. The end-product 1.alpha.,25-dihydroxyergocalciferol is useful in the treatment of disease states which are characterized by insufficient amounts of 1.alpha., 25-dihydroxycholecalciferol.
    Type: Grant
    Filed: December 17, 1984
    Date of Patent: June 17, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Andrew D. Batcho, Alfred Boris, Milan R. Uskokovic
  • Patent number: 4594432
    Abstract: The invention is directed to a process and intermediates for the preparation of 1.alpha.,23(S),25-trihydroxycholecalciferol and 1.alpha.,23(R),25-trihydroxycholecalciferol. The end-products, 1.alpha.,23(S),25-trihydroxycholecalciferol and 1.alpha.,23(R),25-trihydroxycholecalciferol, are useful for the treatment of disease states which are characterized by insufficient amounts of 1,25 dihydroxycholecalciferol.
    Type: Grant
    Filed: December 27, 1983
    Date of Patent: June 10, 1986
    Assignee: Hoffman-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Milan R. Uskokovic, Peter M. Wovkulich
  • Patent number: 4508651
    Abstract: The invention is directed to a process and intermediates for the preparation of 1.alpha.,25-dihydroxyergocalciferol as well as substantially pure and crystalline 1.alpha.,25-dihydroxyergocolciferol. The end-product 1.alpha.,25-dihydroxyergocalciferol is useful in the treatment of disease states which are characterized by insufficient amounts of 1.alpha.,25-dihydroxycholecalciferol.
    Type: Grant
    Filed: March 21, 1983
    Date of Patent: April 2, 1985
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Andrew D. Batcho, Alfred Boris, Milan R. Uskokovic
  • Patent number: 4382031
    Abstract: A process is disclosed for producing d-biotin from L or DL-cystine ester via novel intermediates.
    Type: Grant
    Filed: November 23, 1981
    Date of Patent: May 3, 1983
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Hsi L. Lee, Milan R. Uskokovic
  • Patent number: 4337345
    Abstract: A process is disclosed for producing d-biotin from L cysteine via substituted thiens [3,2c] isoxazoles.
    Type: Grant
    Filed: June 25, 1981
    Date of Patent: June 29, 1982
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Hsi L. Lee, Milan R. Uskokovic
  • Patent number: 4320056
    Abstract: A process is disclosed for producing d-biotin from L or DL-cystine ester via novel intermediates.
    Type: Grant
    Filed: March 12, 1981
    Date of Patent: March 16, 1982
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Hsi L. Lee, Milan R. Uskokovic